1 / 43

Lymphoma 101

Lymphoma 101. Armaan Khalid. What is Lymphoma?. Cancer of the lymph nodes Lymphoma > Leukaemia Commonly manifest by the development of lymphadenopathy at single/multiple sites Classified on basis of histological appearance Hodgkin’s lymphoma (HL) Non-Hodgkin’s lymphoma (NHL).

pia
Télécharger la présentation

Lymphoma 101

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Lymphoma 101 Armaan Khalid

  2. What is Lymphoma? • Cancer of the lymph nodes • Lymphoma > Leukaemia • Commonly manifest by the development of lymphadenopathy at single/multiple sites • Classified on basis of histological appearance • Hodgkin’s lymphoma (HL) • Non-Hodgkin’s lymphoma (NHL)

  3. Hodgkin’s Lymphoma (HL) • Involves primarily the lymph nodes • ♂:♀ is 1.3:1 • Peak incidence is in 3rd decade • Tumour of B Cell origin • Presence of Reed-Sternberg Cells on pathology • Often presents @ a single site & spreads in a predictable fashion

  4. Aetiology of HL • ?Link with EBV • Evidence linking previous infectious mononucleosis with HL • 40% of patients ↑ EBV titres @ time of diagnosis

  5. It’s all about the Reed-Sternberg’s • Hallmark of HL is Reed-Sternberg cells • Large cell w enlarged multilobulated nucleus, prominent nucleoli & abundant eosinophilic cytoplasm • RS cell variants exist in HL subtypes • Staging based on the Ann Arbor Classification • Used to stage both HL & NHL

  6. Classification of HL • Nodular Sclerosing HL (70%) • Typically seen in young adults/adolescents & involving Mediastinal & neck LN • Characteristic cell is the lacunar type RS cells • Overall prognosis is good • Mixed Cellularity HL (25%) • Most common HL in pt > 50y/o, ♂ predominance • Classical RS cells abundant • Assoc with B symptoms • Commonly affects abdominal LN & spleen • Most common HL subtype in HIV +ve population

  7. ‘Classic’ Reed-Sternberg Cells *Common in mixed-cellular subtype HL

  8. ‘Lacunar-Type’ RS Cells *Common in nodular sclerosis subtype HL

  9. Classification of HL • Lymphocyte-rich HL (5%) • Characterised by an inflitrate of many small lymphocytes & RS cells; often an indolent disease • Lymphocyte-depleted HL (1%) • Rare & lacks cellular infiltrate with numerous RS cells • Seen in HL assoc with HIV • Patients usually w advanced stage disease • Nodular Lymphocyte-predominant HL (5%) • Characterised by large number of small resting lymphocytes admixed with benign histiocytes • Classical RS cells difficult to find • Lympho-histiocytic (L&H) variant RS cell (popcorn cell)

  10. Pathogenesis of HL • ??? • Central issue: Lymphocytes of the B-cell lineage not expressing immunoglobulins escape apoptosis • ?Role of EBV • Interferes w normal immune regulatory mechanisms • Often localised to single site & spreads in pedictable fashion

  11. Clinical Features • LN enlargement, esp. Cervical LN • Painless & of rubbery consistency • Supra-diaphragmatic LNs affected in 80% • Hepatosplenomegaly • B symptoms (40%) • Fever, drenching night sweats, weight loss > 10% in 6/12 • Pruritis, fatigue, anorexia, lethargy, malaise • Sg/Sx due to organ involvement • Due to mass effect (Bone, Lung, Cardiac, Gut) • SVC Syndrome • Due to biochemical derangement

  12. Before & After

  13. What is causing the Blockage?

  14. Superior Vena Cava Syndrome • Obstruction of the SVC by an upper mediastinal mass • Sg/Sx • Difficulty breathing/swallowing • Stridor, swollen, oedematous facies • Venous congestion • Ix • Imaging (CXR, CT chest, Invasive contrast venogram) • Rx • Based on what is causing the obstruction • Steroids, diuretics, stenting, chemo/radioRx

  15. Differentials • Infectious Mononucleosis • Lung Ca (Small Cell) • HL • NHL • Rheumatoid Arthritis • Sarcoidosis • SLE

  16. Investigations • FBE • ESR • LFT • Serum LDH (Correlates with ‘bulk’ of disease) • CXR • HIV screening • CT scan • PET scan • Bone marrow aspirate & trephine (BMAT) • LN biopsy

  17. Ann Arbor Staging Classification

  18. Further Designations to Ann Arbor

  19. Management • Rx taken with curative intent • Rx based on: • Anatomical distribution of disease • ‘Bulk’ • Presence/Absence of ‘B’ symptoms

  20. Early Stage (IA, IIA, No Bulk) • Brief chemotherapy + radiotherapy • Example: ABVD or BEACOPP • A = Adriamycin (Doxorubicin) • B = Bleomycin • V = Vinblastine • D = Dacarbazine

  21. Advanced Disease • Cyclical combination chemoRx w or w/o radioRx • Gold standard: ABVD • Pt w bulk disease receive radioRx • Curative 50-60% • Risk of myelosuppression, infertility, 2° malignancy & organ damage

  22. Non-Hodgkin’s Lymphoma (NHL) • Classified separately from HL • 70% - 80% are of B Cell origin • Incidence 15/100 000 per year in devt countries • Slight ♂ predominance • Median age of presentation 55-75y/o • Can be classified on the basis of origin • Tumours of B cells • Tumours of T cells • Tumours of NK cells

  23. Aetiology NHL • Unknown cause; wide geographical variation • ?Envt factors • EBV (Burkitt’s lymphoma) • ↑% of lymphoma in pts with AIDS • H. Pylori in gastric MALT lymphoma

  24. Burkitt Lymphoma (African subtype)

  25. Pathogenesis NHL • Malignant clonal expansion of lymphocytes • Due to errors in gene rearrangements or recombinations • Translocation errors with specific genes • Burkitt’s (c-myc)

  26. Clinical Features • Same as HL* • Same as HL Investigations

  27. Clinical Differences b/w HL & NHL

  28. Follicular B Cell Lymphoma • HOPC Asymptomatic w painless generalised lymphadenopathy • Occurs ↓% in Asian population & predominantly in older people (>20-30y/o) • Ix indicates multiple site involvement (Bone marrow infiltration is common) • Runs a remitting & recurring clinical course • Death due to: • Rx resistant disease • Transformation to Diffuse Large B Cell Lymphoma • Bad prognostic factor, less curable • Effects of Rx

  29. Management • Treat the symptoms, not the numbers • Leave the asymptomatic pt alone • Watchful waiting & repeat biopsies • ChemoRx + RadioRx • rCHOP • r = Rituximab • C = Cyclophosphamide • H = Hydroxydaunorubicin (Doxorubicin) • O = Oncovin (Vincristine) • P = Prednisolone

  30. What is Rituximab? • Trade name: Rituxan or Mabthera • Chimeric monoclonal antibody against CD20, found primarily on the surface of B cells • CD20 widely expressed on B cells, but is absent on terminally differentiated plasma cells • Basically, it induces apoptosis of CD20+ cells

  31. Diffuse Large B Cell Lymphoma • Commonest NHL (50% adults) & invariably fatal w/o Rx • Treat to cure, expectant management inappropriate • >50% of young pts are cured • Contra: Co-morbidities & pt’s will • HOPC • Rapidly progressive lymphadenopathy, symptomatic • Infiltration of extranodal organs • Morphology • Nuclei of neoplastic B cells are huge (x3-4 of resting lymphocytes)

  32. Diffuse Large B Cell Lymphoma

  33. Management • Rx decision based on staging • Cyclical chemoRx + radioRx • rCHOP • Bad prognostic factors • Disease progression during Rx • Failure to achieve complete remission during initial Rx

  34. Burkitt’s Lymphoma • Uncommon in the Western world • Endemic to Africa • Close assoc w EBV • Rapidly fatal w/o Rx • HOPC lymphadenopathy, abdo mass, BM & CNS infiltration (leukaemia & meningitis) • Morphology • Starry sky pattern • Assoc w translocations involving MYC gene

  35. Burkitt’s Lymphoma

  36. Management • Supportive Rx • Hydration • Prevent Tumour Lysis Syndrome! • Cyclical chemoRx + radioRx • rEPOCH • r = Rituximab • E = Etoposide • P = Prednisolone • O = Oncovin (Vincristine) • C = Cyclophosphamide • H = Hydroxydaunorubicin (Doxorubicin) • ?African setting

  37. Peripheral T Cell Lymphoma (Unspecified) • Most common type of adult T-cell lymphoma • Most common subtype of peripheral T Cell lymphoma • Often disseminated & aggressive

  38. Management • Treated similarly to B Cell lymphomas • Cyclical chemoRx + RadioRx • Refer to haematologist • In general, overall Rx strategies are similar but success of complete remission is ↓ than B Cell lymphomas

  39. Tumour Lysis Syndrome • Iatrogenic cause, Rx causes massive breakdown of tumour cells • Intracellular contents released into circulation • Metabolic derangement • Uric acid, potassium & phosphate • Complications • Can precipitate Acute Renal Failure • Mgmt • Identify high-risk pts • Allopurinol given prophylactically • Close monitor of electrolytes • Baseline ECGs & follow-ups

  40. Case Study #1 • 62 y/o woman referred for Ix of neck mass • HOPC • Enlarging L neck lump over last 6/52, no pain • Fatigue, unwell & LOW 3kg • O/E • Afebrile, no pallor/jaundice & peripheral oedema • BP 170/105 & prominent but undisplaced apex beat • L supraclavicular LN (firm, non-tender) • Abdo NAD, soft, tender • X2 enlarged LN in L groin • Urinalysis +1 protein • Other Info • Hx of HTN (felodipine 5mg bd) • Non-smoker & social drinker

  41. Question time • What further info should be elicited from Hx/Ex? • DDx? • Ix? • Staging the pt? • Mgmt & considerations?

  42. Interesting Fact of the Day: Breast implantation & Lymphoma • Epidemiological studies indicate link b/w silicone breast implants & anaplastic large cell lymphoma (ALCL) • ALCL devt in at least 60 women • 2/3 occurred in silicone implants • 1/3 occurred in saline implants • Considered to be related because ALCL occurred uniformly in breast tissue • FDA labelled silicone as inert, Grade 2 • Later relabelled to Grade 3 (somewhat dangerous)

More Related